Indraprastha Medical Corporation Limited (INDRAMEDCO) Fair Value & Analysis

Healthcare · IN · Market cap ₹35.7B

A solid business, currently priced close to our fair value.

What matters now

• The price sits close to our fair value, market and models broadly agree here, little valuation tension.
• A fairly wide model range (₹225.12 to ₹534.24) leaves room in how you read the outcome.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range ₹48.65 – ₹622.80 · fair‑value band ₹225.12 – ₹534.24 · the ₹369.75 price screens above the ₹366.09 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Indraprastha Medical Corporation Limited (INDRAMEDCO) currently trades at ₹369.75, while our model-based Fair Value estimate is ₹366.09, implying the stock looks roughly 1.0% fairly valued today. The Quality Score stands at 68/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Indraprastha Medical Corporation Limited generated revenue of ₹14.8B at a net margin of 12.4%. Revenue grew 9.3% year over year. It earns a return on equity of 27.5%. The balance sheet holds a net cash position of ₹2.3B. Fundamentals as of Aug 13, 2026

Our scenario range runs from ₹225.12 (bear case) to ₹534.24 (bull case); at ₹369.75, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 42% below its 52-week high and 8% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -1%, INDRAMEDCO screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: DCF Models (₹402.29) versus Asset-Based (₹54.11). Highest evidence: Growth DCF (80).

Key figures & financial health

Quality Score breakdown

About the company

Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, …

Full company description

Indraprastha Medical Corporation Limited provides hospital services in India. The company offers services primarily in the areas of sugar, genomic medicine, elder care, anesthesiology, bariatric and metabolic surgery, bone marrow transplant, dental and cosmetic clinic, dermatology, dietetics and clinical nutrition, vascular and endovascular surgery, endocrinology, ENT, fetal medicine, general and laparoscopic surgery, gynecology and obstetrics, hyperbaric oxygen therapy, IVF, neonatology, nephrology, nuclear medicine, ophthalmology, pediatric sciences, urology, and plastic surgery, as well as pediatric urology and surgery, physiotherapy and rehabilitation, psychiatry and clinical psychology, radiology and radio diagnosis, respiratory, rheumatology, spine surgery, urology and andrology, cardiology, oncology, emergency, gastroenterology, neuroscience, critical care, orthopedics, robotic surgery, and organ transplant, as well as laboratory services, interventional medicine, preventive medicine, and sleep medicine. Indraprastha Medical Corporation Limited was founded in 1983 and is based in New Delhi, India.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Indraprastha Medical Corporation Limited reported revenue of ₹14.8B in FY2026 versus ₹8.9B in FY2022, a compound +13.7%/yr. Reported net income was ₹1.8B in FY2026, compounding +33.0%/yr from FY2022.

Watch INDRAMEDCO: get an alert when its fair value changes →

Peer Group

Medical Care Facilities · 267 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.